Lipigon Pharmaceuticals
0.00 SEK
-18.42 %
Less than 1K followers
LPGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-18.42 %
-53.03 %
-79.33 %
-63.95 %
-97.72 %
-96.61 %
-99.27 %
-99.94 %
-99.95 %
Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are primarily treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market.
Read moreMarket cap
1.88M SEK
Turnover
40.57K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
14/5
2026
Interim report Q1'26
18/5
2026
General meeting '26
25/8
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Styrelsen för Lipigon föreslår att årsstämman beslutar om avnotering från Nasdaq First North Growth Market
Lipigon publicerar bokslutskommuniké 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools